Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation

Francesco Saia; Pim De Feyter; Patrick W. Serruys; Pedro A. Lemos; Chourmouzios A. Arampatzis; Guy R. Hendrickx; Nicholas Delarche; Dick Goedhart; Emmanuel Lesaffre; Angelo Branzi

doi:10.1016/j.amjcard.2003.08.076

Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation

Francesco Saia, Pim De Feyter, Patrick W. Serruys, Pedro A. Lemos, Chourmouzios A. Arampatzis, Guy R. Hendrickx, Nicholas Delarche, Dick Goedhart, Emmanuel Lesaffre, Angelo Branzi

Erasmus MC

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

12 Citations (Scopus)

Abstract

We assessed the impact of long-term fluvastatin treatment on adverse atherosclerotic cardiac events (cardiac death, myocardial infarction, and revascularization excluding repeat interventions due to restenosis in the first 6 months) in 847 patients (fluvastatin [n = 417] or placebo [n = 430]) with average cholesterol levels treated with stents in the Lescol Intervention Prevention Study (LIPS). During the 4-year follow-up period, fluvastatin significantly decreased total cholesterol and low-density lipoprotein cholesterol levels and decreased the risk of first adverse atherosclerotic cardiac events by 30% compared with placebo (95% confidence interval -49 to -3.4, p = 0.03).

Original language	English
Pages (from-to)	92-95
Number of pages	4
Journal	American Journal of Cardiology
Volume	93
Issue number	1
DOIs	https://doi.org/10.1016/j.amjcard.2003.08.076
Publication status	Published - 1 Jan 2004
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.amjcard.2003.08.076

Cite this

@article{5724d49b0547477182a2bd2b044ff963,

title = "Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation",

abstract = "We assessed the impact of long-term fluvastatin treatment on adverse atherosclerotic cardiac events (cardiac death, myocardial infarction, and revascularization excluding repeat interventions due to restenosis in the first 6 months) in 847 patients (fluvastatin [n = 417] or placebo [n = 430]) with average cholesterol levels treated with stents in the Lescol Intervention Prevention Study (LIPS). During the 4-year follow-up period, fluvastatin significantly decreased total cholesterol and low-density lipoprotein cholesterol levels and decreased the risk of first adverse atherosclerotic cardiac events by 30\% compared with placebo (95\% confidence interval -49 to -3.4, p = 0.03).",

author = "Francesco Saia and \{De Feyter\}, Pim and Serruys, \{Patrick W.\} and Lemos, \{Pedro A.\} and Arampatzis, \{Chourmouzios A.\} and Hendrickx, \{Guy R.\} and Nicholas Delarche and Dick Goedhart and Emmanuel Lesaffre and Angelo Branzi",

year = "2004",

month = jan,

day = "1",

doi = "10.1016/j.amjcard.2003.08.076",

language = "English",

volume = "93",

pages = "92--95",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation

AU - Saia, Francesco

AU - De Feyter, Pim

AU - Serruys, Patrick W.

AU - Lemos, Pedro A.

AU - Arampatzis, Chourmouzios A.

AU - Hendrickx, Guy R.

AU - Delarche, Nicholas

AU - Goedhart, Dick

AU - Lesaffre, Emmanuel

AU - Branzi, Angelo

PY - 2004/1/1

Y1 - 2004/1/1

N2 - We assessed the impact of long-term fluvastatin treatment on adverse atherosclerotic cardiac events (cardiac death, myocardial infarction, and revascularization excluding repeat interventions due to restenosis in the first 6 months) in 847 patients (fluvastatin [n = 417] or placebo [n = 430]) with average cholesterol levels treated with stents in the Lescol Intervention Prevention Study (LIPS). During the 4-year follow-up period, fluvastatin significantly decreased total cholesterol and low-density lipoprotein cholesterol levels and decreased the risk of first adverse atherosclerotic cardiac events by 30% compared with placebo (95% confidence interval -49 to -3.4, p = 0.03).

AB - We assessed the impact of long-term fluvastatin treatment on adverse atherosclerotic cardiac events (cardiac death, myocardial infarction, and revascularization excluding repeat interventions due to restenosis in the first 6 months) in 847 patients (fluvastatin [n = 417] or placebo [n = 430]) with average cholesterol levels treated with stents in the Lescol Intervention Prevention Study (LIPS). During the 4-year follow-up period, fluvastatin significantly decreased total cholesterol and low-density lipoprotein cholesterol levels and decreased the risk of first adverse atherosclerotic cardiac events by 30% compared with placebo (95% confidence interval -49 to -3.4, p = 0.03).

UR - https://www.scopus.com/pages/publications/9144231239

U2 - 10.1016/j.amjcard.2003.08.076

DO - 10.1016/j.amjcard.2003.08.076

M3 - Article

AN - SCOPUS:9144231239

SN - 0002-9149

VL - 93

SP - 92

EP - 95

JO - American Journal of Cardiology

JF - American Journal of Cardiology

IS - 1

ER -

Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this